Investigator

Mostafa Kamal Masud

CCQ Next Generation Cancer Research Fellow · The University of Queensland, Australian Institute for Bioengineering and Nanotechnology

About

MKMMostafa Kamal Mas…
Papers(2)
A MOF-derived iron ox…Plasmonic Mesoporous …
Collaborators(3)
Yusuke YamauchiEmtiaz AhmedMd. Shahriar A. Hossa…
Institutions(1)
The University Of Que…

Papers

Plasmonic Mesoporous Gold‐Based SERS Biosensor for Ovarian Cancer‐Derived Extracellular Vesicles

AbstractExtracellular vesicles (EVs) are lipids bilayer‐delimited particles carrying bioactive molecules such as proteins, lipids, and nucleic acids, reflecting the physiological state of their origin. Found in biofluids like saliva, urine, blood, and peritoneal fluid, EVs serve as promising minimally invasive biomarkers for several conditions including cancer. However, achieving high sensitivity and specificity in EV detection remains technically challenging. Placental Alkaline Phosphatase (PLAP), an enzyme primarily expressed in the placenta during pregnancy, has emerged as a clinically relevant biomarker in gynecological malignancies, including ovarian cancer (OC). In this study, a nanoengineered mesoporous gold (mAu)‐based Surface‐Enhanced Raman Spectroscopy (SERS) platform is reported for the rapid and ultrasensitive detection of PLAP‐positive EVs in OC patients. The mAu offers high surface roughness, enabling numerous localized plasmonic hotspots that amplify Raman signals and improve probe and antibody loading. This allowed the detection of as few as 100 EVs mL−1 with excellent reproducibility (RSD < 5%,n = 3). In clinical validation (n = 30), the assay achieved 90% sensitivity (95% CI: 60%–100%) and 85% specificity (95% CI: 15%–100%) in distinguishing OC patients from those with benign and healthy controls, demonstrating superior performance compared to CA‐125. The mAu‐SERS platform shows considerable promise as a minimally invasive and clinically applicable diagnostic strategy for OC, especially for differential diagnosis for their ability to distingluis between benign and OC conditions.

61Works
2Papers
3Collaborators
Ovarian NeoplasmsLung NeoplasmsBiomarkers, TumorCell Line, TumorTumor Suppressor Protein p53Carcinoma, Non-Small-Cell LungNeoplasms

Positions

2024–

CCQ Next Generation Cancer Research Fellow

The University of Queensland · Australian Institute for Bioengineering and Nanotechnology

2022–

Postdoctoral Research Fellow

The University of Queensland · Australian Institute for Bioengineering and Nanotechnology (AIBN)

2021–

Research Fellow (Honorary)

The University of Queensland · Australian Institute for Bioengineering and Nanotechnology (AIBN)

2020–

JSPS Postdoctoral Fellow

National Institute for Materials Science · International Center for Materials Nanoarchitectonics (MANA)

2020–

Research Associate

The University of Queensland · Australian Institute for Bioengineering and Nanotechnology (AIBN)

2015–

Assistant Professor

Shahjalal University of Science and Technology · Department of Biochemistry and Molecular Biology

2013–

Lecturer

Shahjalal University of Science and Technology · Department of Biochemistry and Molecular Biology

2011–

Laboratory Officer

Coats plc · Coats Color lab, Chittagong

Education

2020

PhD

University of Queensland · Australian Institute for Bioengineering and Nanotechnology

2018

PhD

University of Wollongong · Australian Institute for Innovative Materials (AIIM)

2011

Master of Science

Shahjalal University of Science and Technology · Department of Chemistry

2009

Bachelor of Science

Shahjalal University of Science and Technology · Department of Chemistry

Country

AU

Keywords
Magnetic NanoparticlesBiosensorRNA biomarkersExosomeElectrochemical sensor